Tiseo, Marcello
 Distribuzione geografica
Continente #
NA - Nord America 193
EU - Europa 136
AS - Asia 114
AF - Africa 6
OC - Oceania 1
SA - Sud America 1
Totale 451
Nazione #
US - Stati Uniti d'America 188
CN - Cina 54
SG - Singapore 42
RU - Federazione Russa 31
IE - Irlanda 22
SE - Svezia 20
FR - Francia 19
IT - Italia 14
DE - Germania 12
HK - Hong Kong 10
GB - Regno Unito 9
CA - Canada 5
TG - Togo 4
BE - Belgio 3
AZ - Azerbaigian 2
ID - Indonesia 2
LY - Libia 2
PH - Filippine 2
AR - Argentina 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
ES - Italia 1
FI - Finlandia 1
KG - Kirghizistan 1
LV - Lettonia 1
NZ - Nuova Zelanda 1
UA - Ucraina 1
VN - Vietnam 1
Totale 451
Città #
Singapore 38
Chandler 36
Dublin 22
Ashburn 16
Jacksonville 12
Beijing 11
Hong Kong 10
Lawrence 7
Princeton 7
Sindelfingen 7
Wilmington 5
Frankfurt am Main 4
Kent 4
Lomé 4
Seattle 4
Brussels 3
Guangzhou 3
Hangzhou 3
London 3
Santa Clara 3
Southend 3
Taiyuan 3
Toronto 3
Washington 3
Antwerp 2
Boardman 2
Dallas 2
Jakarta 2
Jinan 2
Liberty 2
Los Angeles 2
Messina 2
Mountain View 2
New York 2
Ottawa 2
Verona 2
Auckland 1
Baku 1
Bishkek 1
Buenos Aires 1
Columbus 1
Haikou 1
Helsinki 1
Irving 1
Lamezia Terme 1
Laurel 1
Milan 1
Moscow 1
Newark 1
Prague 1
Redwood City 1
Riga 1
Somerville 1
Stockholm 1
Tangshan 1
Tianjin 1
Turin 1
Yicheng 1
Totale 260
Nome #
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 57
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations 54
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study 50
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors 44
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status 42
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study 36
Listening understanding and acting (lung): focus on communicational issue in thoracic oncology 33
Detection of ALK fusion variants by RNA-based NGS and clinical outcome correlation in NSCLC patients treated with ALK-TKI sequences 31
Exploring the role of respiratory microbiome in lung cancer: A systematic review 25
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG 25
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients 23
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients 18
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 10
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study 10
Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment 10
Totale 468
Categoria #
all - tutte 2.781
article - articoli 2.781
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.562


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205 0 0 0 0 0 1 0 0 0 0 3 1
2020/202118 0 0 0 2 6 5 0 0 0 0 5 0
2021/202247 2 9 0 5 0 0 5 4 0 0 8 14
2022/2023125 7 11 15 15 12 31 1 7 17 0 7 2
2023/2024124 4 9 11 15 12 18 9 9 1 5 23 8
2024/2025147 13 11 14 69 11 29 0 0 0 0 0 0
Totale 468